目的 分析2019—2021年安徽医科大学附属六安医院保肝类药物使用情况以及应用趋势，旨在为临床保肝类药物合理用药提供参考依据。方法 回顾性分析安徽医科大学附属六安医院2019年1月—2021年12月年保肝药类药物的销售金额、使用频度（DDDs）、日均费用（DDC）等数据进行汇总统计并分析。结果 2019—2021年保肝类药物销售金额总体呈下降趋势，其中口服保肝类药物金额总体变化不大，构成比呈增长趋势。抗炎保肝类药物销售金额连续2年位居第1位。熊去氧胆酸胶囊和甘草酸二铵肠溶胶囊DDDs连续3年位居前3位。注射用门冬氨酸鸟氨酸、异甘草酸镁注射液DDC排名连续3年保持前2位。大部分保肝类药物B/A值均接近于1，说明同步性良好。结论 安徽医科大学附属六安医院保肝类药物使用基本合理，符合安全、有效、经济用药原则。

Objective To analysis the usage and application trend of hepatoprotective drugs in Lu’an Hospital Affiliated to Anhui Medical University, so as to provide reference basis for the rational use of hepatoprotective drugs. Methods The application data of hepatoprotective drugs in Lu’an Hospital Affiliated to Anhui Medical University from January 2019 to December 2021 were statistically analyzed in terms of total sale amount, defined daily dose system (DDDs), daily drug cost (DDC), the ranking ratio (B/A), and so on. Results From 2019 to 2021, the sales amount of hepatoprotective drugs showed a downward trend, in which the amount of oral liver protection drugs showed little change, and the composition ratio showed an increasing trend. The sales amount of anti-inflammatory and hepatoprotective drugs ranked first for two consecutive years. The DDDs of Ursodeoxycholic Acid Capsules and Diammonium Glycyrrhizinate Enteric-coated Capsules ranked the top three for three consecutive years. DDC of Ornithine Aspartate for Injection and Magnesium Isoglycyrrhizinate Injection ranked the top two for three consecutive years. Most B/A values of hepatoprotective drugs were close to 1, indicating good synchronization. Conclusion The utilization of hepatoprotective drugs in Lu’an Hospital Affiliated to Anhui Medical University is basically reasonable, in line with the medication principles of safe, effective and economic.

R975

安徽高校自然科学研究项目(KJ2021A0342);安徽医科大学校科研基金项目(2020xkj231)